JNPMEDI, a consulting firm specializing in artificial intelligence (AI) driven drug discovery and innovative medical device development, announced on Thursday its plans to strengthen its position as a global partner in these fields, building on last year’s successes.
A JNPMEDI spokesperson reported impressive growth, with a 500% revenue increase in 2024 followed by a 250% rise in 2025, achieving both quantitative expansion and qualitative advancement. The company secured over 100 new clients last year, including major players like Samjin Pharmaceutical, Handok, DDH, ReadyCure, and MEDI-IoT, while also landing more than 20 global clinical projects.
This growth underscores the market’s recognition of JNPMEDI’s expertise in clinical operations, data management, and global regulatory compliance.
Enhancing End-to-End Solutions from Study Design to Regulatory Approval
In the past year, JNPMEDI focused on bolstering its comprehensive solutions covering the entire clinical development lifecycle, from study design to operations, data management, and regulatory compliance.
The company streamlined administrative processes and improved data management efficiency in clinical settings. It also expanded its solutions to meet the stringent data standards and submission requirements of key regulatory bodies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Ministry of Food and Drug Safety (MFDS).
A standout success for JNPMEDI was the approval of EverEx’s confirmatory clinical trial for MORA Cure, a digital therapeutic device (DTx). JNPMEDI’s management of the trial operations and data led to EverEx securing Korea’s first approval for a musculoskeletal digital therapeutic.
This achievement in the emerging field of digital therapeutics demonstrates that JNPMEDI’s clinical support solutions are instrumental in navigating new regulatory frameworks and securing approvals.
Expanding Global Reach and Introducing Cost-Effective Clinical Models
Leveraging its expertise, JNPMEDI has been collaborating with numerous pharmaceutical companies, accumulating success stories in global market entry and traditional drug development. The company’s AI-based platform offers a ‘cost-effective clinical’ model, significantly reducing time and expenses compared to conventional methods, thereby accelerating clients’ drug commercialization timelines.
For the coming year, JNPMEDI has set its sights on ‘global expansion’ and advancement in drug and medical device development. The company plans to leverage its extensive clinical industry experience and advanced infrastructure to aggressively pursue international markets.
To support these goals, JNPMEDI is actively recruiting top talent. Recent high-profile hires include Kim Yu-mi, a global medical regulatory expert and former MFDS deputy director, and Na Hyun-hee, a clinical development strategist with over two decades of experience in pharmaceuticals and contract research organizations (CROs).
JNPMEDI aims to broaden its strategic partnerships with global pharmaceutical and biotech firms, enhance its multinational clinical trial capabilities, and establish itself as a comprehensive clinical operations partner meeting international standards. The company plans to set up an Asia-Pacific (APAC) regional hub this year and accelerate its entry into the U.S. market.
Jung Kwon-ho, Chief Executive Officer (CEO) of JNPMEDI, reflected that 2025 was a pivotal year, showcasing both the growth and the core strengths of the solutions. In 2026, it aims to solidify our position as a key global partner for companies developing new drugs and medical devices, helping to build a foundation for international growth.